PE-backed Agenus closes buy of 4-Antibody
Agenus has completed its acquisition of 4-Antibody AG. The transaction, which consisted of Agenus buying all outstanding stock of 4-Antibody for approximately 3.3 million shares of Agenus common stock, could surpass $40 million. Also, Dr. Shahzad Malik, general partner at Advent Venture Partners, will join Agenus’ board of directors after the deal closes. Based in Europe, 4-Antibody AG, which is backed by Advent Venture Partners, is a biopharmaceutical company. Agenus is backed by Iroquois Capital, Downsview Capital and Hudson Capital.
13 February 2014•3 mins read
